RA Capital Entities Acquire Additional Artiva Biotherapeutics Shares

RA Capital Management, L.P. and related entities have filed a Form 4 disclosing significant purchases of Artiva Biotherapeutics, Inc. (ARTV) common stock between June 12-16, 2026. The investment group acquired a total of 531,326 shares across three transactions at weighted average prices ranging from $8.57 to $8.99 per share. The purchases were made by RA Capital Healthcare Fund LP, with Laura Stoppel, a Principal of the Adviser, serving on Artiva's board of directors. Following these transactions, the reporting entities collectively hold substantial positions in the company, including 264,571 shares held by RA Capital Nexus Fund, 826,832 shares by RA Capital Nexus Fund III, and 68,320 shares in a separately managed account. The filing indicates the transactions were executed in multiple trades within specific price ranges, with the reporting persons undertaking to provide detailed transaction information upon request.